Quebec City, June 1, 2022 - Pharma in silica is initiating the preclinical study of its product candidate OpPacli™ (optimized paclitaxel) against non-small cell lung cancer (NSCLC).

The study is financed by the company's own funds and by grants totaling $650K (Mitacs-Acceleration, NRC-IRAP, IQ Innovation, PSO-Validation, PAEN-MÉI). Professors Nicolas Bertrand and Sébastien Fortin of the CHU de Québec/Université Laval are co-directors of several parts of the study.

The company thanks MITACS, PARI and MÉI for their financial support, as well as Axelys and Québec International for their intermediation.